Menu
Annual · values20252024202320222021202020192018
Operating Cash Flow-32.38 M USD-31.54 M USD-37.61 M USD-45.08 M USD-41.39 M USD-30.63 M USD-20.77 M USD-18.39 M USD
Depreciation & Amortization1.10 M USD1.10 M USD1.40 M USD1.40 M USD700000 USD300000 USD200000 USD100000 USD
Stock-Based Compensation21.23 M USD22.95 M USD22.10 M USD16.45 M USD10.53 M USD3.20 M USD364000 USD366000 USD
Capital Expenditures452000 USD1.45 M USD807000 USD1.32 M USD3.67 M USD911000 USD720000 USD316000 USD
Cash Flow from Investing30.48 M USD17.48 M USD-2.01 M USD-4.22 M USD-46.26 M USD12.69 M USD-14.23 M USD200000 USD
Cash Flow from Financing833000 USD1.36 M USD21.40 M USD2.42 M USD4.46 M USD234.83 M USD45.62 M USD12.11 M USD
Dividends Paid
Stock Buybacks0 USD27000 USD26000 USD21000 USD12000 USD0 USD
Free Cash Flow-32.83 M USD-32.98 M USD-38.42 M USD-46.40 M USD-45.06 M USD-31.54 M USD-21.48 M USD-18.71 M USD

Pulmonx Corporation is a leading medical technology company specializing in minimally invasive treatments for chronic obstructive pulmonary disease (COPD). The company focuses on developing and commercializing advanced technologies that offer new options for patients suffering from lung disorders. One of its flagship products, the Zephyr Valve, is a tiny device designed for bronchoscopic lung volume reduction in severe emphysema patients, providing an alternative to invasive surgical procedures. Pulmonx's innovative solutions impact the healthcare sector by improving patient outcomes and offering healthcare providers effective, less invasive treatment options. By driving advancements in respiratory care, Pulmonx plays a significant role in the growing medical device industry, particularly within the respiratory segment, as the demand for novel therapeutic options for chronic lung diseases increases. Headquartered in Redwood City, California, the company collaborates with medical professionals worldwide to expand access to its life-changing technologies.